WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 204320
CAS#: 1173699-31-4
Description: AMG 337 is an orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-Met, thereby disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein.
MedKoo Cat#: 204320
Name: AMG-337
CAS#: 1173699-31-4
Chemical Formula: C23H22FN7O3
Exact Mass: 463.1768
Molecular Weight: 463.4734
Elemental Analysis: C, 59.60; H, 4.78; F, 4.10; N, 21.16; O, 10.36
Synonym: AMG337; AMG-337; AMG 337.
IUPAC/Chemical Name: (R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one
InChi Key: DWHXUGDWKAIASB-CQSZACIVSA-N
InChi Code: InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1
SMILES Code: O=C1C2=C(N=CC(OCCOC)=C2)C=CN1[C@@H](C3=NN=C4C(F)=CC(C5=CN(C)N=C5)=CN43)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 463.4734 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Lee J, Tran P, Klempner SJ. Targeting the MET Pathway in Gastric and
Oesophageal Cancers: Refining the Optimal Approach. Clin Oncol (R Coll Radiol).
2016 Feb 12. pii: S0936-6555(16)00035-2. doi: 10.1016/j.clon.2016.01.009. [Epub
ahead of print] PubMed PMID: 26880063.
2: Boezio AA, Copeland KW, Rex K, K Albrecht B, Bauer D, Bellon SF, Boezio C,
Broome MA, Choquette D, Coxon A, Dussault I, Hirai S, Lewis R, Lin MJ, Lohman J,
Liu J, Peterson EA, Potashman M, Shimanovich R, Teffera Y, Whittington DA, Vaida
KR, Harmange JC. Discovery of
(R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-y
l)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and
Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo
Antitumor Activity. J Med Chem. 2016 Feb 11. [Epub ahead of print] PubMed PMID:
26812066.
3: Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S,
Fasola G, Scartozzi M. Tracking the 2015 Gastrointestinal Cancers Symposium:
bridging cancer biology to clinical gastrointestinal oncology. Onco Targets Ther.
2015 May 22;8:1149-56. doi: 10.2147/OTT.S82624. eCollection 2015. Review. PubMed
PMID: 26045669; PubMed Central PMCID: PMC4447178.
